1-800-452-8106      Contact      Careers
Emdeon  EMDEON  I-WEB  PATIENT BILL PAY

Laboratory Test Detail

Last Updated: April 18, 2024 @ 9:13 am

2860

T-SPOT, Tuberculosis (TB)

Specimen:Collect:
  • Two Green Top (Li Heparin)
Submit:
  • Two 4 mL (Min:3 mL) Whole blood in Green Top (Li Heparin). Submit Ambient.

Also Acceptable:
  • One 10 mL (Min:6 mL) Whole blood in Green Top (Li Heparin). Submit Ambient.
Special Handling:
  • Sample can only be collected MONDAY-FRIDAY.
    Immunocompromised patients will require Four 4 mL Lithium Heparin tubes (minimum 12 mL).
    Call Pendleton Client Service Department for any extenuating circumstances.
Rejection Criteria:
  • EDTA, Oxalate, Citrate
  • Less than 4mL
    Refrigerated
    Specimens must arrived in Pendleton to be processed within 32 hours of collection.
    Critical Ambient
Stability:Ambient: 32 Hour(s); Refrigerated: Unacceptable; Frozen: Unacceptable; Incubated: Unacceptable
Methodology:
  • Enzyme-linked Immunospot (ELISPOT)
  • Interferon-Gamma Release Assay (IGRAs)
Performed:Tuesday, Wednesday, Thursday, Friday, Saturday
Reported:2-3 Day(s)
CPT Codes:
  • 86481
Interpretive Data:Please see report for interpretive data.

NEGATIVE - The test result is NEGATIVE if both (Panel A minus Nil Control) and (Panel B minus Nil Control) are less than or equal to 4. This includes values less than zero.

POSITIVE - The test result is POSITIVE if (Panel A minus Nil Control) and/or (Panel B minus Nil Control) is greater than or equal to 8.

BORDERLINE - The test result is BORDERLINE if (Panel A minus Nil Control) or (Panel B minus Nil Control) is equal to 5, 6, or 7. It is recommended to repeat the T-SPOT.TB testing by submitting a new specimen.

Diagnosing or excluding tuberculosis disease, and assessing the probability of LTBI, requires a combination of epidemiological, historical, medical and diagnostic findings that should be taken into account when interpreting T-SPOT.TB test results. Refer to the most recent CDC guidance (http://www.cdc.gov/nchstp/tb) for detailed recommendations about diagnosing TB infection (including disease) and selecting persons for testing.

The performance of T-SPOT.TB has not been adequately evaluated with specimens from individuals younger than 17 years, in pregnant women, and in patients with hemophilia.

A false positive result was obtained for T-SPOT.TB when tested in subjects with M. xenopi, M. kansasii and M. gordonae. While ESAT-6 and CFP10 antigens are absent from BCG strains of M. bovis and from most environmental mycobacteria, it is possible that a positive T-SPOT.TB result may be due to infection with M. kansasii, M. szulgai, M. gordonae or M. marinum. Alternative tests would be required if these infections are suspected.

A negative test result does not exclude the possibility of exposure to, or infection with M. tuberculosis. Patients with recent exposure to TB infected individuals exhibiting a negative T-SPOT.TB result should be considered for retesting within 6 weeks or if other relevant clinical symptoms indicate possible infection.

A positive test result does not rule in active TB disease; other tests should be performed to confirm the diagnosis of active TB disease such as sputum smear and culture, PCR, and chest radiography.

T-SPOT.TB has not been evaluated in subjects who have received >1 month of anti-TB therapy.
Components:
  • 2861 - INTERPRETATION
  • 2862 - NIL (NEG) CONTROL
  • 2863 - PNL A SPOT COUNT
  • 2864 - PNL B SPOT COUNT
  • 2865 - POSITIVE CONTROL
Print Friendly, PDF & Email

Disclaimer:
It is preferable to locate tests on the website and not rely on printed test information, which may soon be out of date.
Updated test information can only be guaranteed by using this website.